Surprise snub by FDA of AcelRx's Zalviso
This article was originally published in Scrip
Executive Summary
The FDA surprised nearly everyone by rejecting AcelRx Pharmaceuticals' new drug application (NDA) for its pre-programmed, non-invasive, handheld system Zalviso, which delivers 15mcg per dose as needed of sufentanil, an opioid, allowing hospital patients to self-dose in managing their pain.
You may also be interested in...
Pain In The (ER) Battlefield: AcelRx Reports Positive ARX-04 Results
AcelRx reports fast-acting, pain-reducing data for ARX-04 in emergency room-treated trauma patients, which is the setting that most closely resembles battlefield situations experienced by personnel in the US military – the Phase III program's co-funder.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.